LS Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
LS Pharma
Largest movements
- Cash +€42,780
up €42,780 (+30.1%), from €142,271 to €185,051
mainly Net result for the year (+€65,358) and Trade debts (+€38,274)
- Receivables within one year +€40,251
up €40,251 (+45.4%), from €88,745 to €128,997
of which Trade receivables: +€29,822
- Stocks and contracts +€30,560
up €30,560 (+9.5%), from €320,730 to €351,291
- Tangible fixed assets -€15,924
down €15,924 (-16.3%), from €97,511 to €81,586
of which Furniture and vehicles: -€9,736
- Reserves +€65,000
up €65,000 (+36.5%), from €178,059 to €243,059
- Trade debts +€38,274
up €38,274 (+44.9%), from €85,168 to €123,442
- Other debts -€7,975
down €7,975 (-51.0%), from €15,653 to €7,678
- Staff costs +€27,606
up €27,606 (+12.8%), from €216,250 to €243,856
- Gross operating margin +€13,642
up €13,642 (+3.9%), from €348,477 to €362,120
- Taxes -€3,798
down €3,798 (-12.4%), from €30,516 to €26,718
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €651,352 | €749,318 | +€97,966 | +15.0% |
| Fixed assets | 21/28 | €97,511 | €81,586 | -€15,924 | -16.3% |
| Tangible fixed assets | 22/27 | €97,511 | €81,586 | -€15,924 | -16.3% |
| Land and buildings | 22 | €40,458 | €35,134 | -€5,324 | -13.2% |
| Plant, machinery and equipment | 23 | €10,530 | €9,666 | -€864 | -8.2% |
| Furniture and vehicles | 24 | €46,523 | €36,786 | -€9,736 | -20.9% |
| Current assets | 29/58 | €553,842 | €667,732 | +€113,890 | +20.6% |
| Stocks and contracts in progress | 3 | €320,730 | €351,291 | +€30,560 | +9.5% |
| Stocks | 30/36 | €320,730 | €351,291 | +€30,560 | +9.5% |
| Amounts receivable within one year | 40/41 | €88,745 | €128,997 | +€40,251 | +45.4% |
| Trade receivables | 40 | €82,216 | €112,038 | +€29,822 | +36.3% |
| Other amounts receivable | 41 | €6,529 | €16,958 | +€10,429 | +159.7% |
| Cash at bank and in hand | 54/58 | €142,271 | €185,051 | +€42,780 | +30.1% |
| Deferred charges and accrued income | 490/1 | €2,094 | €2,393 | +€299 | +14.3% |
| Total equity and liabilities | 10/49 | €651,352 | €749,318 | +€97,966 | +15.0% |
| Equity | 10/15 | €490,117 | €555,475 | +€65,358 | +13.3% |
| Contributions | 10/11 | €3,530 | €3,530 | = | 0.0% |
| Reserves | 13 | €178,059 | €243,059 | +€65,000 | +36.5% |
| Distributable reserves | 133 | €178,059 | €243,059 | +€65,000 | +36.5% |
| Profit (loss) carried forward | 14 | €308,528 | €308,886 | +€358 | +0.1% |
| Amounts payable | 17/49 | €161,235 | €193,843 | +€32,608 | +20.2% |
| Amounts payable after more than one year | 17 | €0 | - | = | |
| Financial debts | 170/4 | €0 | - | = | |
| Amounts payable within one year | 42/48 | €161,235 | €189,043 | +€27,808 | +17.2% |
| Current portion of amounts payable after more than one year | 42 | €1,390 | €0 | -€1,390 | -100.0% |
| Financial debts | 43 | €15,000 | €15,000 | = | 0.0% |
| Other loans | 439 | €15,000 | €15,000 | = | 0.0% |
| Trade debts | 44 | €85,168 | €123,442 | +€38,274 | +44.9% |
| Suppliers | 440/4 | €85,168 | €123,442 | +€38,274 | +44.9% |
| Taxes, remuneration and social security | 45 | €44,024 | €42,923 | -€1,101 | -2.5% |
| Taxes | 450/3 | €14,076 | €11,352 | -€2,724 | -19.4% |
| Remuneration and social security | 454/9 | €29,948 | €31,570 | +€1,623 | +5.4% |
| Other amounts payable | 47/48 | €15,653 | €7,678 | -€7,975 | -51.0% |
| Accrued charges and deferred income | 492/3 | - | €4,800 | +€4,800 | |
| Non-recurring operating income | 76A | €11,540 | €0 | -€11,540 | -100.0% |
| Remuneration, social security and pensions | 62 | €216,250 | €243,856 | +€27,606 | +12.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €19,376 | €21,471 | +€2,095 | +10.8% |
| Other operating charges | 640/8 | €1,235 | €911 | -€324 | -26.2% |
| Non-recurring operating charges | 66A | €0 | - | = | |
| Gross operating margin | 9900 | €348,477 | €362,120 | +€13,642 | +3.9% |
| Operating profit (loss) | 9901 | €111,616 | €95,881 | -€15,735 | -14.1% |
| Financial income | 75/76B | €0 | €1 | +€1 | |
| Recurring financial income | 75 | €0 | €1 | +€1 | |
| Financial charges | 65/66B | €3,851 | €3,806 | -€45 | -1.2% |
| Recurring financial charges | 65 | €3,851 | €3,806 | -€45 | -1.2% |
| Profit (loss) for the period before taxes | 9903 | €107,765 | €92,076 | -€15,689 | -14.6% |
| Income taxes | 67/77 | €30,516 | €26,718 | -€3,798 | -12.4% |
| Profit (loss) for the period | 9904 | €77,249 | €65,358 | -€11,891 | -15.4% |
| Profit (loss) for the period to be appropriated | 9905 | €77,249 | €65,358 | -€11,891 | -15.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.